Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Zoetis Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $15.38 (market cap $1.06B), while Zoetis Inc trades at $73.64 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 28.5× YieldMax MSTR Option Income Strategy ETF's market cap, and Zoetis Inc pays a 2.9% dividend while YieldMax MSTR Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax MSTR Option Income Strategy ETF for 30 Days and Zoetis Inc for 70 Days on average.
| MSTY | ZTS | |
|---|---|---|
Market Cap | $1.06B | $30.20B |
Volume | 2,402,888 | 6,175,327 |
Sector | Income / Options Overlay | Health |
52-Week High | $67.85 | $147.53 |
52-Week Low | $11.55 | $69.09 |
Typical Hold Time | 30 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.83, down 5.61% today amid bearish technical signals. The ETF shows mixed sentiment with Seeking Alpha rating it Hold despite a 100.32% annualized distribution rate. Recent articles highlight significant NAV erosion, with $10,000 investments declining to approximately $6,614 over six months according to 24/7 Wall Street analysis from July 2026.
The fund's high distribution strategy comes with substantial principal erosion risk. While weekly dividends provide income, the structural design returns investor capital as distributions. Analyst consensus remains cautious due to the fund's dependence on MSTR volatility and ongoing NAV decline, making this suitable only for sophisticated investors understanding the income-principal tradeoff.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
